MEPC’s Milton Park has signed Momentum Bioscience on a long-term lease.
The company, which is at the forefront of developing diagnostic solutions for sepsis, will occupy 6,000 sq ft of space. The facility is expected to support the development and testing of its flagship product SepsiSTAT.
MEPC worked with Momentum Bioscience to design the custom-built labs and communal breakout workspaces.
Tom Booker, commercial manager at MEPC, said: “Momentum Bioscience’s work in rapid sepsis diagnostics aligns perfectly with the forward-thinking innovators at Milton Park and we look forward to seeing them grow in their new custom-built facility.”
Image © MEPC
Send feedback to Evelina Grecenko
